R
Ronald G. Thomas
Researcher at University of California, San Diego
Publications - 158
Citations - 25876
Ronald G. Thomas is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Randomized controlled trial & Dementia. The author has an hindex of 65, co-authored 145 publications receiving 23504 citations. Previous affiliations of Ronald G. Thomas include American Institutes for Research & University of Southern California.
Papers
More filters
Journal ArticleDOI
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
Mary Sano,Christopher Ernesto,Ronald G. Thomas,Melville R. Klauber,Kimberly Schafer,Michael Grundman,Peter B. Woodbury,John H. Growdon,Carl W. Cotman,Eric Pfeiffer,Lon S. Schneider,Leon J. Thal +11 more
TL;DR: In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Journal ArticleDOI
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Ronald C. Petersen,Ronald G. Thomas,Michael Grundman,David A. Bennett,Rachelle S. Doody,Steven H. Ferris,Douglas Galasko,Shelia Jin,Jeffrey Kaye,Allan I. Levey,Eric Pfeiffer,Mary Sano,Christopher H. van Dyck,Leon J. Thal +13 more
TL;DR: Vitamin E had no benefit in patients with mild cognitive impairment and donepezil therapy was associated with a lower rate of progression to Alzheimer's disease during the first 12 months of treatment, a finding supported by the secondary outcome measures.
Journal ArticleDOI
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody,Ronald G. Thomas,Martin R. Farlow,Takeshi Iwatsubo,Bruno Vellas,Steven Joffe,Karl Kieburtz,Rema Raman,Xiaoying Sun,Paul S. Aisen,Eric Siemers,Hong Liu-Seifert,Richard C. Mohs +12 more
TL;DR: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with mild Alzheimer's disease.
Journal ArticleDOI
Length of clinical trials of dementia drugs : Position paper from the international working group on harmonization of dementia drug guidelines
Douglas Galasko,David A. Bennett,Mary Sano,Chris Ernesto,Ronald G. Thomas,Michael Grundman,Steven H. Ferris +6 more
TL;DR: This paper developed a set of informant-based items describing performance of activities of daily living (ADL) by patients with Alzheimer's disease (AD) to identify which ADL are useful for assessment of patients in clinical trials.
Journal ArticleDOI
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Rachelle S. Doody,Rema Raman,Martin R. Farlow,Takeshi Iwatsubo,Bruno Vellas,Steven Joffe,Karl Kieburtz,Feng He,Xiaoying Sun,Ronald G. Thomas,Paul S. Aisen,Eric Siemers,Gopalan Sethuraman,Richard C. Mohs +13 more
TL;DR: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability, and semagACestat was associated with more adverse events, including skin cancers and infections.